NewAmsterdam Pharma N.V. (NAMSW)
NewAmsterdam Pharma Statistics
Share Statistics
NewAmsterdam Pharma has 223.92M shares outstanding. The number of shares has increased by 0.36% in one year.
| Shares Outstanding | 223.92M |
| Shares Change (YoY) | 0.36% |
| Shares Change (QoQ) | -8.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 119.54M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is undefined and the forward PE ratio is null. NewAmsterdam Pharma's PEG ratio is undefined.
| PE Ratio | undefined |
| Forward PE | n/a |
| PS Ratio | 71.91 |
| Forward PS | n/a |
| PB Ratio | 3.18 |
| P/FCF Ratio | n/a |
| PEG Ratio | undefined |
Enterprise Valuation
NewAmsterdam Pharma has an Enterprise Value (EV) of 577.36M.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.95, with a Debt / Equity ratio of undefined.
| Current Ratio | 6.95 |
| Quick Ratio | 6.95 |
| Debt / Equity | undefined |
| Debt / EBITDA | - |
| Debt / FCF | - |
| Interest Coverage | undefined |
Financial Efficiency
Return on Equity is -0.61% and Return on Invested Capital is -57.46%.
| Return on Equity | -0.61% |
| Return on Assets | -0.51% |
| Return on Invested Capital | -57.46% |
| Revenue Per Employee | $205.85K |
| Profits Per Employee | $-2.85M |
| Employee Count | 62 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 27K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0, so NewAmsterdam Pharma's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 12.02 |
| 200-Day Moving Average | 9.59 |
| Relative Strength Index (RSI) | 35.07 |
| Average Volume (20 Days) | - |
Income Statement
In the last 12 months, NewAmsterdam Pharma had revenue of 12.76M and earned -176.94M in profits. Earnings per share was -2.15.
| Revenue | 12.76M |
| Gross Profit | 12.76M |
| Operating Income | -165.73M |
| Net Income | -176.94M |
| EBITDA | -176.86M |
| EBIT | -165.73M |
| Earnings Per Share (EPS) | -2.15 |
Balance Sheet
The company has 340.45M in cash and 60K in debt, giving a net cash position of 340.39M.
| Cash & Cash Equivalents | 340.45M |
| Total Debt | 60K |
| Net Cash | 340.39M |
| Retained Earnings | -316.97M |
| Total Assets | 439.19M |
| Working Capital | 396.62M |
Cash Flow
In the last 12 months, operating cash flow was -141.22M and capital expenditures -24K, giving a free cash flow of -141.24M.
| Operating Cash Flow | -141.22M |
| Capital Expenditures | -24K |
| Free Cash Flow | -141.24M |
| FCF Per Share | -1.72 |
Margins
Gross margin is 100%, with operating and profit margins of -1298.56% and -1386.36%.
| Gross Margin | 100% |
| Operating Margin | -1298.56% |
| Pretax Margin | -1255.57% |
| Profit Margin | -1386.36% |
| EBITDA Margin | -1385.76% |
| EBIT Margin | -1298.56% |
| FCF Margin | -1106.68% |
Dividends & Yields
NAMSW does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for NAMSW.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 19.1 |
| Piotroski F-Score | 1 |